Torrey Growth & Income Advisors Sells 7,450 Shares of Tempus AI, Inc. $TEM

Torrey Growth & Income Advisors decreased its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 41.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,427 shares of the company’s stock after selling 7,450 shares during the period. Torrey Growth & Income Advisors’ holdings in Tempus AI were worth $880,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Eagle Health Investments LP acquired a new position in shares of Tempus AI during the first quarter worth $11,588,000. Aristotle Atlantic Partners LLC purchased a new stake in shares of Tempus AI during the 1st quarter valued at $6,179,000. Headlands Technologies LLC purchased a new stake in shares of Tempus AI during the 2nd quarter valued at $2,689,000. Odyssean LLC acquired a new stake in shares of Tempus AI in the 2nd quarter worth $897,000. Finally, Fagan Associates Inc. acquired a new stake in shares of Tempus AI in the 3rd quarter worth $5,265,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TEM. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Raymond James Financial set a $80.00 target price on Tempus AI in a research report on Wednesday, September 2nd. Lake Street Capital cut Tempus AI to a “hold” rating in a research note on Monday, July 20th. Robert W. Baird raised their price target on Tempus AI from $85.00 to $92.00 and gave the stock an “outperform” rating in a report on Tuesday, November 3rd. Finally, Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $76.00 in a report on Tuesday, September 1st. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.37.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James Rogers sold 26,313 shares of Tempus AI stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the completion of the sale, the chief executive officer directly owned 100,000 shares in the company, valued at $7,747,000. This trade represents a 71.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,237,227 shares of company stock worth $85,388,983 in the last 90 days. Corporate insiders own 24.26% of the company’s stock.

Tempus AI Stock Up 11.0%

Shares of TEM stock opened at $84.44 on Tuesday. The stock’s 50-day simple moving average is $71.73 and its 200-day simple moving average is $57.34. The company has a debt-to-equity ratio of 2.70, a quick ratio of 3.16 and a current ratio of 2.61. The firm has a market capitalization of $15.24 billion, a PE ratio of -79.66 and a beta of 3.61. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $89.09.

Tempus AI (NASDAQ:TEM) last released its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The firm had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The company’s revenue was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.46) earnings per share. Equities analysts expect that Tempus AI, Inc. will post -1.20 earnings per share for the current year.

Tempus AI Profile

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research.

The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Founded in 2015 by entrepreneur Eric Lefkofsky, Tempus is headquartered in Chicago.